DOJ lawsuit reins in inappropriate ICD use
Jul 06, 2018•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
A reanalysis of the ATLAS ACS 2-TIMI 51 trial shows rivaroxaban in a different light; cerebral protection may be appropriate in all TAVR procedures, regardless of anatomy; The Feds' big stick vs. carrot approach worked in cutting inappropriate ICD use: and canagliflozin's perported amputation risk didn't make a showing in a real-word study.
For the best experience, listen in Metacast app for iOS or Android